Introduction
between patient groups, which simply does not exist in real life. Furthermore, whether a patient is categoBefore attempting to discuss the management of anae-rized as 'pre-' or 'post-' dialysis is not wholly determia with epoetin in 'pre-dialysis' patients, it is essential mined by his or her clinical condition, but is also influenced by local resources. The physiological
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Canadian Multicentre Study in Early Renal Disease son, the incidence of LVH in patients commencing dialysis is 75% in Canada [6 ] . The existence and relevance of a progressive continuum Patients who have LVH at baseline are significantly of renal insufficiency is illustrated by the findings of older (mean age 59 years vs 53 years, P<0.003), have the Canadian Multicentre Study in Early Renal Disease significantly worse renal function (mean creatinine [2] [3] [4] [5] . This is an ongoing, prospective, longitudinal clearance of 33 ml/min vs 39.2 ml/min, P<0.002) and cohort study of the progression of renal disease prior have a significantly lower haemoglobin (12.1 g/dl vs to intervention, conducted at eight academic nephrol-13.1 g/dl, P<0.001). As might be expected, these ogy centres across Canada. All patients with creatinine patients have significantly lower plasma calcium and clearances of between 20 and 75 ml/min are evaluated greater systolic and mean arterial pressures. serially for renal function. Cardiac status is evaluated However, it is important to note that LVH is defined using annual two-dimensional echocardiograms to on a population basis (LVMI >131 g/m2 for men and measure left ventricular mass index (LVMI ), and >100 g/m2 for women) and is simply a categorization cardiac symptoms and events are recorded. Serial of a continuous variable. Perhaps a more clinically measurements are performed for standard laboratory relevant measurement is change in LVMI. A clinically variables, and for haematological, biochemical and significant increase in LVMI can be defined as an endocrine parameters. Clinical records are also kept of increase of >20% from baseline, or an absolute value blood pressure, medications and body weight.
of >20 g/m2. Based on these criteria, a significant To date, 446 patients (mean age: 56 years) have increase in LVMI occurred during the study in 23% of entered the study. Approximately half the patients patients. At baseline, those patients who did and those have moderate renal insufficiency (creatinine clearance who did not have a subsequent increase in LVMI of 25-50 ml/min),~30% have a creatinine clearance showed no significant differences in age, serum creatiof 50-75 ml/min and~20% have a creatinine clear-nine, creatinine clearance, haemoglobin, mean arterial ance of <25 ml/min. Just over two-thirds (68%) of the pressure or the use of angiotensin-converting enzyme patients are male, which is typical of the dialysis (ACE) inhibitors or calcium-channel blockers. population in Canada. In this cohort, 30% of the After 12 months, haemoglobin and systolic blood patients are diabetic and 86% are hypertensive (i.e. pressure were the only variables that differed significhave a mean arterial pressure of >105 mmHg at entry, antly between patients with and those without an increase in LVMI. Haemoglobin had decreased by a or are receiving antihypertensive therapy); the mean mean of 0.75 g/dl in patients with an increase in LVMI, creatinine clearance is 36 ml/min (corrected for age compared with 0.1 g/dl in patients with no increase in and weight), the mean haemoglobin is 12.6 g/dl and LVMI (P<0.001). Contrary to expectations, it the mean parathyroid hormone (PTH ) is 11.7 pmol/l appeared that treatment with ACE inhibitors did not (twice the upper limit of normal ), despite a normal have a protective effect against an increase in LVMI. mean calcium (2.3 mmol/l ).
These findings demonstrate that the cardiovascular One of the most striking findings so far is that many consequences of renal anaemia begin relatively early of the patients already have a marked degree of left in the course of renal failure, and that an increase in ventricular hypertrophy (LVH ) at baseline. The preva-LVMI is closely linked to the change in haemoglobin lence of LVH is related to the degree of renal dysover time. function ( Figure 1 ): 26% at a creatinine clearance of 50-75 ml/min; 33% at 25-50 ml/min; and 41% at Recommendations regarding definitions <25 ml/min (P<0.01 vs 50-75 ml/min). For compariBased on the evidence presented, the workshop participants concluded that the term 'progressive renal insufficiency' is more appropriate than 'pre-dialysis'. Furthermore, it was recommended that anaemia itself should be defined as any haemoglobin less than the normal physiological range (gender-adjusted). In addition to the absolute haemoglobin, the rate of decline in haemoglobin may also be important. However, defining anaemia relative to normal haemoglobin does not necessarily mean that haemoglobin should be normalized. As discussed below, the optimum target haemoglobin for patients with progressive renal insufficiency remains as controversial as that for patients on dialysis. tionship between degree of renal dysfunction (creatinine clearance ml/min) and prevalence of LVH. Also shown is the preva-progressive renal insufficiency lence of LVH in dialysis patients in Canada. It is evident that a substantial proportion of patients develop LVH long before dialysis
Having established that the adverse cardiovascular is initiated, and that LVH becomes increasingly prevalent as renal function declines. (Adapted from [6 ] ).
effects of anaemia are apparent quite early in the A. Levin 68 course of renal failure, the workshop participants then tion, energy, cognitive function, sexual function and other parameters is an increase in health-related quality considered the potential benefits and risks of correcting the anaemia of progressive renal insufficiency with of life. This applies not only to dialysis patients but also to those with progressive renal insufficiency [16 ] . epoetin.
Studies have demonstrated that epoetin can be used However, demonstration of beneficial effects in patients who are not yet on dialysis is not sufficient. It must safely and effectively to increase the haemoglobin in anaemic patients with progressive renal insufficiency also be established that administration of epoetin does not accelerate the decline in renal function in this [7] [8] [9] . What effect, however, does increasing haemoglobin have on the clinical manifestations of anaemia? patient group.
Anaemia has well-known negative effects on physical, cognitive, emotional and sexual function. Equally Does epoetin accelerate renal failure? important, however, are its effects on the cardiovascular system, which may ultimately result in LVH and its consequences, myocardial infarction and heart To understand the issues surrounding the effects of failure. The importance of anaemia as a risk factor in epoetin on renal function, both animal and human patients on haemodialysis has been clearly demon-studies must be considered. strated [10, 11] . Haemoglobin concentrations of ∏8 g/dl are associated with a 2-fold increase in the Animal studies odds of death when compared with haemoglobin of 10-11 g/dl [12] . Furthermore, anaemia predicts Animal data from a study by Garcia et al. in 1988 have generated some concern regarding a potential mortality independently of age, diabetes mellitus, cardiac failure, hypoalbuminaemia, serum creatinine, adverse effect of epoetin treatment on renal function [25] . In a rat model of chronic renal insufficiency, the mean arterial pressure or echocardiographic heart disease.
researchers found that preventing anaemia with epoetin increased systemic and glomerular hypertension and LVH is already present in 75% of patients starting dialysis and, like anaemia, is an independent predictor glomerular injury. In contrast, renal function was actually preserved by anaemia in this study. of mortality [6 ] . Anaemia during the pre-dialysis period is believed to be a key factor in the development
The study used 5/6 nephrectomized rats, divided into three groups: controls (nephrectomy only); of LVH in patients with renal failure [4, 13] . Since there is a continuum of renal failure, treating anaemia epoetin-treated anaemic (nephrectomy plus epoetin treatment to maintain a stable haematocrit); and should be beneficial, whether or not the patient is on dialysis. One would also expect that correction of untreated anaemic (nephrectomy plus bleeding and a low-iron diet). The animals were monitored for 12 anaemia would at least partially reverse the adverse consequences of anaemia in all patients with renal weeks.
As expected, the control rats showed a reduction in failure.
This hypothesis is supported by the finding that haematocrit from 50 to 42%. In the untreated anaemic rats, haematocrit was reduced to~30%, while in the correction of anaemia with epoetin brings about partial regression of LVH in patients with end-stage renal epoetin-treated animals it remained stable at 50%.
Striking differences were found between the groups disease ( ESRD) [14] . While regression of LVH has yet to be demonstrated for patients in the pre-dialysis with regard to systolic blood pressure (measured by the tail cuff method ) and urinary protein excrephase, beneficial cardiovascular effects have been shown in terms of exercise capacity [8, [15] [16] [17] [18] . tion ( Figure 3 ) [25] . In the epoetin-treated anaemic animals, blood pressure was highest at baseline and Furthermore, dialysis patients treated with epoetin are less likely to be hospitalized than those who are not increased sharply during the first 6 weeks of the study (after which the animals died ). Blood pressure also receiving this therapy [19] .
In addition to positive effects on the cardiovascular increased in the control group, levelling off at~6 weeks, with the animals surviving to 12 weeks. In the system, correction of anaemia with epoetin results in many other benefits. In patients with progressive renal untreated anaemic group, blood pressure was initially low and showed little increase during the study. insufficiency, the effects on energy levels and work capacity are similar to those seen in haemodialysis Urinary protein excretion mirrored systolic blood pressure, being very marked in the epoetin-treated patients ( Figure 2) [8]. Treatment of anaemia has been shown to improve cognitive function not only in anaemic animals, very slight in the untreated anaemic group and intermediate in the controls. Filtration dialysis patients [20, 21] but also in progressive renal insufficiency patients [16 ] . Likewise, sexual function pressure followed the same pattern. There was very early glomerular sclerosis in the epoetin-treated improves in both patients on dialysis [22] and those with progressive renal insufficiency [16 ] . This effect is anaemic animals; 33% of glomeruli were found to be sclerosed after 6 weeks. The control group took 12 probably a result of beneficial effects on pituitarygonadal feedback [23] . Epoetin has also been reported weeks to reach 30% sclerosis, whereas the untreated anaemic animals showed only 6% sclerosis after 12 to enhance immune responses in patients with ESRD [24] .
weeks. The authors concluded: 'these results suggest that The overall effect of improvements in physical func- 3 . Changes in systolic blood pressure (SBP) and urinary protein excretion ( U prot ·V ) in 5/6 nephrectomized rats. Untreated control rats showed sustained systemic hypertension and developed progressive proteinuria. In epoetin-treated rats, hypertension was aggravated by normalization of haematocrit. These rats developed marked proteinuria and died 6 weeks after renal ablation. In untreated rats that were also made anaemic, anaemia ameliorated systemic hypertension and significantly limited proteinuria. Values are means±SEM. $P<0.05 vs control; +P<0.05 vs epoetin. (Reproduced with permission from [25] ).
anemia is a hemodynamically favorable adaptation to clearance in a 6 month study of 12 pre-dialysis patients [15] . In a study of 26 patients followed-up for a period chronic renal disease and that its overly vigorous of 2.4-24 months, Lim et al. found that neither epoetin correction may have adverse renal hemodynamic and administration nor a normal haematocrit accelerated structural consequences'.
the deterioration of renal function (measured by the In a later study, however, Ruedin et al. showed that slope of 1/serum creatinine vs time) [27] . In a study of control of systemic hypertension could completely pre-16 patients (follow-up: 12-65 weeks), Abraham et al. vent any adverse effect of epoetin treatment in rats [26 ] .
found no adverse effect of epoetin administration either on glomerular filtration rate (GFR) (measured by Human studies inulin clearance) or on the slope of 1/serum creatinine Despite the somewhat disturbing results of the animal vs time [28] . study reported above, several human studies provide
In a 12 week study of eight pre-dialysis patients, no evidence to suggest that treatment with epoetin Frenken et al. [29] found no effect of epoetin treatment may accelerate renal decline [15, 18, [27] [28] [29] [30] .
on GFR, renal blood flow or filtration fraction. Similarly, in a 12 week study of 12 patients, Clyne and Teehan et al. found no effect of epoetin on creatinine Jogenstrand [18] found no adverse effects of epoetin on GFR. The Austrian Multicenter Study of 123 epoetin-treated patients found no alterations in the slope of the curve of renal decline (1/serum creatinine) over a 12 week follow-up period [7] .
More recently, Roth et al. [30] conducted the first large-scale study of the effects of epoetin on renal function in a large number of patients with progressive renal insufficiency, using a reliable measure of GFR ([125I ]iothalamate clearance). This 48 week, randomized, open-label, multicentre study included 83 anaemic patients with a serum creatinine of 3-8 mg/dl (265-707 mmol/l ) who were not yet on dialysis. At   Fig. 4 . Survival function for time to initiation of dialysis in 83 entry, patients were required to have a haematocrit of anaemic pre-dialysis patients followed up for 48 weeks with and Á30%, a mean arterial pressure of <114 mmHg, a without epoetin treatment. There was no significant effect of epoetin daily protein intake of 0.8±0.32 g/kg/day, and good treatment on survival function. P-values for comparing equality of survival curves: log-rank test, P=0.9955; Wilcoxon test, P=0.8613.
control of serum phosphorus (<5.5 mg/dl ); these (Reproduced with permission from [30] ).
parameters were controlled within the same range throughout the study.
A 2 month stabilization phase (for control of blood renal failure in pre-dialysis patients [31] . In this study, pressure and nutritional parameters) was followed by untreated anaemic controls (n=31) were compared a 48 week treatment phase. Forty patients were with anaemic patients treated with epoetin (n=42) and randomized to the untreated arm and 43 patients to with non-anaemic controls (n=35). The primary end the treatment arm (50 IU/kg epoetin subcutaneously point for each patient was a doubling of the baseline (s.c.) three times weekly). When the haematocrit creatinine, yielding cumulative renal survival rates plotreached 36%, the epoetin dosage was titrated to mainted against time. Cumulative renal survival in the tain a haematocrit of 35%. GFRs were measured at epoetin-treated patients and non-anaemic controls was intervals throughout the study (weeks 1, 8, 32, 48 or significantly better than in untreated anaemic patients, early termination).
a difference which seemed to indicate better renal The majority of epoetin-treated patients (79%) survival in non-diabetic epoetin-treated patients. The achieved the target haematocrit of 36% (average just authors suggested that 'reversal of anemia by epoetin under 35%). In contrast, the haematocrits of untreated can retard the progression of renal failure, especially patients did not change significantly during the study.
in non-diabetic patients, provided that blood pressure GFR, mean arterial blood pressure and daily protein control, rate of increase in hematocrit, and dietary intake did not differ significantly between the two protein restriction are appropriate'. groups during the study. The statistically significant increase in haematocrit in the epoetin-treated group was not associated with any acceleration of deteriNeed for further studies oration in GFR ( Table 1 ) [30] , nor was there any difference between the groups in time to initiation of To date, there is no evidence from human studies dialysis (Figure 4 ) [30] . The authors concluded that indicating that treating anaemia with epoetin in epoetin therapy improves anaemia in pre-dialysis progressive renal insufficiency patients has any detripatients and does not accelerate progression to ESRD. mental effect on progression of renal failure. However, Recently, it has actually been claimed that correction most studies have included relatively small numbers of of anaemia with epoetin can reduce the progression of patients, and have had short follow-up periods. Under these circumstances, and given the usual wide vari- Any potential adverse effects of epoetin on renal
There was no significant effect of epoetin treatment on renal function. (Data from [30] ).
function are likely to be mediated via effects on blood
The management of anaemia in pre-dialysis patients 71 pressure. In the rat study by Garcia et al., for example, hypertension, mild or moderate hyperparathyroidism and metabolic acidosis. there was a sharp, uncontrolled increase in blood pressure in epoetin-treated animals, which probably caused the acceleration in renal failure [25] .
Should haemoglobin be normalized in patients with
Partial correction of anaemia with epoetin in CRF progressive renal insufficiency? patients causes hypertension in~20% of patients [33] . However, most studies have found that an epoetininduced increase in blood pressure can be controlled There is a difference between treating anaemia and readily with antihypertensive medication in the normalizing haemoglobin. At present, there is no evimajority of patients. dence either to recommend or to advise against early Nevertheless, certain reservations must be borne in treatment to normalize haemoglobin in patients with mind. For example, it is becoming increasingly evident progressive renal insufficiency. Long-term, randomthat the optimum target blood pressure for patients ized, controlled trials are needed to reassess both the with progressive renal disease may be much less than optimal timing and the targets for treatment of the currently accepted 140/90 mmHg [34] . No study anaemia in this patient group. In particular, the relative has yet shown that blood pressure can be reduced to benefits and risks of normalizing haemoglobin in less than this in epoetin-treated pre-dialysis patients. progressive renal insufficiency patients must be evaluFurthermore, none of the studies conducted so far has ated. It is important to identify appropriate end points used 24 h blood pressure monitoring to ascertain for such studies, which might include time to renal adequate blood pressure control.
replacement therapy, rate of progression, exercise In addition, successful reduction of blood pressure capacity, left ventricular growth and geometry, and in essential hypertension has not resulted in as large a cardiac events. reduction in cardiac mortality as might be expected on the basis of epidemiological studies. In hypertensive
Role of adjuvant therapy
patients with progressive renal insufficiency, as in other categories of hypertensive patients, it is unclear whether effective treatment of hypertension will offer protection Studies on the efficacy and safety of epoetin treatment against cardiac events. In the Modification of Diet in in patients with progressive renal insufficiency should Renal Disease (MDRD) study [35] , it was not possible also investigate the role of adjuvant therapies. The use to demonstrate a protective effect of low-protein diet of appropriate adjuvant therapies could increase the or aggressive blood pressure therapy in a cohort of effectiveness of epoetin therapy in those progressive several hundred patients who were followed for many renal insufficiency patients who may require high doses years. Finally, it is not known how the different to achieve target haemoglobin. therapeutic agents that may be used in progressive renal insufficiency patients interact. For example, the Iron supplementation study by Frenken et al. demonstrated that the efferent renal vasodilative response to an ACE inhibitor is Diminished iron stores and/or decreased availability of iron are the most common causes of relative resistblunted in patients treated with epoetin [29] .
ance to epoetin in uraemic patients [37] . Intravenous (i.v.) iron is now widely accepted as the most effective
Who to treat
route of administration for iron supplementation for patients on dialysis [38] . However, much less is known about the effectiveness of and optimal route of adminisThe workshop concluded that the evidence from human studies shows epoetin to be effective in tration for iron supplementation in patients with progressive renal insufficiency. Bone marrow studies in correcting anaemia in patients with progressive renal insufficiency. There is no evidence of short-term (up to uraemic undialysed patients show that~94% have reduced iron stores [39] . Possible reasons for this 48 weeks) adverse effects of correcting anaemia with epoetin in patients with advanced renal insufficiency include reduced iron intake (due to anorexia or a lowprotein diet), reduced iron absorption or gastroand a haematocrit of 27-34%, provided that blood pressure is controlled.
intestinal blood loss. Silverberg et al. [40, 41] have reported the efficacy of Progressive renal insufficiency might be defined in terms of: (i) a GFR of <50% of normal (adjusted for i.v. iron in patients with progressive renal insufficiency, both with and without concurrent epoetin treatment. age and gender); and (ii) structural evidence of renal disease. Such patients have an~80% chance of pro-In a study of 33 anaemic undialysed patients (creatinine clearances of 10-40 ml/min), previously treated with gressing to end-stage renal failure [36 ] .
Serum creatinine per se is uninformative, and it is oral iron, 200 mg i.v. iron sucrose was administered once monthly for 5 months [41] . One month after the therefore preferable to use calculated or measured creatinine clearances. In addition to anaemia, patients last dose, the mean increase in haematocrit percentage points was 1.9, compared with baseline values. In the considered for epoetin treatment would also be expected to have evidence of other pathophysiological 22 patients in whom haematocrit increased, the mean increase in haematocrit percentage points was 3.0. consequences of impaired renal function, such as enhance the effectiveness of epoetin treatment and All patients had initial serum ferritin <600 mg/l and improve patients' well-being and health status. transferrin saturation <35%. Three weeks after the Potential roles have been identified for -carnitine, last dose, the mean rise in haematocrit percentage vitamin B 6, vitamin B 12 , folic acid, ascorbic acid and points was 0.46 in the epoetin group, 3.17 in the i.v. vitamin D ( W. H. Hö rl, this volume). However, nearly iron group and 4.24 in the combination group.
all of the research on nutritional supplements has been A subset of those patients originally given i.v. iron conducted in patients on dialysis. was then given either a second course of i.v. iron alone -Carnitine is perhaps the best-researched of the or the i.v. iron-epoetin combination. In these two nutritional supplements in haemodialysis patients. groups, the mean increases in haematocrit percentage Patients with renal insufficiency are believed to have points after both treatment courses together were 5.89 abnormal renal handling of carnitine; carnitine is also and 6.88, respectively. A repeat course was also given lost during dialysis [43] . Carnitine appears to be to a subset of those who were originally given the i.v. necessary for the structure and function of the red cell iron-epoetin combination, and the mean increase in membrane [44, 45] , and administration of -carnitine haematocrit percentage points after both courses has been shown to reduce erythrocyte membrane together was 5.34. In total,~40% of patients who had fragility in dialysed patients [46 ] . been given i.v. iron alone and 75% of those who had
In haemodialysis patients, administration of -carnireceived the combination of i.v. iron and low-dose tine (without epoetin) has been reported to increase epoetin achieved the target haematocrit of 35%.
haemoglobin, as well as to correct lipid abnormalities, Patients who reached the target haematocrit were and to improve muscular and cardiac function [43] . then followed-up for a mean of 9 months. Almost 30% The response to epoetin in anaemic patients with of those who initially had received the i.v. iron-epoetin ESRD is correlated with serum carnitine [47] . combination were able to maintain the target haemato-Moreover, -carnitine administration has been shown crit for several months without epoetin therapy.
to improve the response to epoetin [48, 49] . However, In none of the original three treatment groups did until recently, the potential role of -carnitine in initial serum ferritin, erythropoietin, transferrin recep-patients with progressive renal insufficiency prior to tor protein or parathyroid hormone correlate with dialysis had not been examined. haematocrit response. However, in the group that Teplan et al. conducted a randomized controlled received i.v. iron only, initial and final serum creatinine trial of the effects of adjuvant therapy with -carnitine and initial percentage transferrin saturation values in anaemic patients with progressive renal insufficiency correlated negatively with haematocrit response. The [50, 51] . A total of 38 patients (20 men, 18 women) rate of decline in renal function, as measured by the with severe renal insufficiency, aged 32-68 years, were change in l/serum creatinine over time, improved followed for 1 year. All patients had low creatinine significantly with treatment of the anaemia.
clearance rates (12-36 ml/min) and symptomatic renal These results demonstrate not only that i.v. iron anaemia (haemoglobin <10 g/dl, haematocrit <30%). therapy and epoetin therapy have additive effects in Patients were given a diet containing 0.6 g/kg body correcting renal anaemia in patients with progressive weight protein per day (mean energy value 145 kJ/kg renal insufficiency, but also that i.v. iron therapy alone body weight per day). The diet was supplemented with may be sufficient in some cases. These findings are keto amino acids at a dose of 0.1 g/kg body weight similar to those obtained by the same authors in per day. dialysis patients [42]. It is not necessarily possible, After correcting serum iron, ferritin and transferrin however, to extrapolate from data in dialysis patients. saturation, the patients were divided into two groups: Further studies are therefore needed to compare i.v. (i) epoetin alfa at a low dose of 20 IU/kg s.c. three with oral iron in patients with mild-to-moderate times per week (the dose subsequently was adjusted in progressive renal insufficiency, and to examine the individual cases), together with -carnitine at an oral optimal dose, timing and monitoring of i.v. iron admin-dose of 1.0 g (n=18); (ii) standard diet but no istration in progressive renal insufficiency patients.
additional therapy (n=20). In the meantime, the workshop concluded that red Over a follow-up period of 1 year, patients receiving blood cell indices should be reviewed regularly in epoetin plus -carnitine showed significant increases in progressive renal insufficiency patients receiving albumin, body mass index, and transferrin, and epoetin, with a view to initiating iron therapy whenever decreases in Whitehead quotient and the phenylnecessary. Early iron therapy is important to maximize alanine5tryptophan ratio compared with baseline. the effectiveness of epoetin in correcting anaemia, and Lipid metabolism also improved in this group of to allow it to be used in the most economic way patients. During the study, the mean dose of epoetin alfa declined from an initial value of 3900 IU/week to possible.
The management of anaemia in pre-dialysis patients 73 2500 IU/week (P<0.01). Significant decreases were decrease in haemoglobin may be as relevant as the absolute haemoglobin. noted in triglycerides (from 4.26 to 2.24 mmol/l ), total cholesterol ( TC ) (from 7.31 to 5.82 mmol/l ) and low-$ The adverse effects of haemoglobin on left ventricular mass are apparent early in the course of density lipoprotein (LDL) cholesterol (from 5.24 to 3.75 mmol/l ). There were significant increases in progressive renal insufficiency, and become more severe as renal function declines. high-density lipoprotein (HDL) cholesterol (from 0.92 to 1.4 mmol/l ), the HDL:TC ratio (from 12 to 24%) $ Correction of anaemia in progressive renal insufficiency patients improves physical function, and the HDL 2 cholesterol:HDL 3 cholesterol ratio (from 5.69 to 2.06). energy, cognitive function, sexual function and other parameters, though effects on LVH have yet These findings suggest that, in patients with progressive renal insufficiency, concomitant administration of to be demonstrated in controlled studies.
$
Although a study in 5/6 nephrectomized rats has -carnitine might reduce the dose of epoetin required and have beneficial effects on lipid metabolism.
suggested that administration of epoetin may accelerate a decline in renal function, no evidence However, it should be noted that the beneficial effects seen in this study may also have been due to the overall for any such adverse effect has been seen in human studies lasting up to 48 weeks. metabolic stabilization of patients (including enhanced metabolism of amino acids and saccharides) and the $ Treatment of anaemia with epoetin may be considered in patients with progressive renal concomitant administration of keto amino acids. A study comparing epoetin therapy alone with epoetin insufficiency (GFR of <50% of normal and structural evidence of renal disease), provided blood plus -carnitine is needed to establish whether -carnitine supplementation adds to the efficacy of pressure is well controlled.
There is no evidence either for or against increasing epoetin in progressive renal insufficiency patients.
haemoglobin to normal in this patient group.
Unrecognized 'iron-responsive' anaemia may Workshop recommendations occur in patients with progressive renal insuffiThere is reasonably good evidence for the usefulness ciency; early iron therapy is important to achieve of iron supplementation in progressive renal insuffithe full benefits of epoetin. ciency patients prior to dialysis. There is also some $ Adequate nutrition is important in progressive evidence for adjuvant therapy with -carnitine in this renal insufficiency; the role of supplements such as patient group. Other nutritional supplements, such as -carnitine, B 6, B 12 and folic acid requires further folic acid, ascorbic acid and vitamins B 6 , B 12 and D, investigation. have yet to be investigated in progressive renal
There is still a great deal to be learnt about the insufficiency patients. management of anaemia in patients with progressive It cannot be assumed that findings from patients on renal insufficiency. However, studies of this patient dialysis can be extrapolated to this patient group. For group have already been initiated. There is clearly a example, the effects of dialysis itself may influence the role for epoetin in ameliorating the symptoms of nutritional status of dialysis patients in a way that anaemia in these patients, and good theoretical reasons does not apply to undialysed patients. In addition, to believe that early correction of anaemia may help a significant proportion of patients with CRF will to reduce the toll of anaemia-related cardiac disease. be anaemic for reasons other than erythropoietin deficiency. The workshop participants therefore recommended that all anaemic patients be evaluated routinely for folic acid, thyroid hormone and B 12
deficiencies, References as well as iron status.
